title: PBT-1 Prana Biotechnology.
abstract: PBT-1 (clioquinol), is undergoing phase II clinical trials by Prana Biotechnology Ltd for the potential treatment of Alzheimer's disease. By October 2004, the company had planned phase III trials for the first half of 2005.
authors.affiliation: Axovan Ltd, Innovation Center, Allschwil, Switzerland. richard@huckle2.fsbusiness.co.uk
authors.forename: Richard
authors.initials: R
authors.lastname: Huckle
mesh_terms: D000544:Alzheimer Disease / Q000188:drug therapy* / Q000378:metabolism; D016229:Amyloid beta-Peptides / Q000378:metabolism; D000818:Animals; D002986:Clinical Trials as Topic; D007464:Clioquinol / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D006801:Humans
chemical_list: D016229:Amyloid beta-Peptides; D007464:Clioquinol